Fig 1: PDE4 expression in small intestinal cells. (A) IEC-6 cells were treated with different concentrations of LPS for 24 h to detect its effect on cell viability. (B) Reverse transcription-quantitative PCR analysis and (C) western blotting were performed to detect the expression levels of PDE4A, PDE4B and PDE4D in cells treated with increasing doses of LPS. *P<0.05, ***P<0.001; n≥3. PDE4, phosphodiesterase 4; LPS, lipopolysaccharide.
Fig 2: PDE4 expression in septic small intestinal tissue. (A) H&E staining was used to observe the pathological changes in small intestinal tissue (magnification, x200). (B) LDH, DAO and iFABP levels in septic small intestinal tissue were detected using respective assay kits. (C) Reverse transcription-quantitative PCR analysis and (D) western blotting were conducted to detect the expression levels of PDE4A, PDE4B and PDE4D in septic small intestinal tissue. **P<0.01, ***P<0.001; n≥3. PDE4, phosphodiesterase 4; LDH, lactate dehydrogenase; DAO, D-amino acid oxidase; iFABP, intestinal fatty acid binding protein; CLP, cecal ligation and puncture.
Supplier Page from Abcam for Anti-PDE4 antibody